Immix Biopharma, Inc.
IMMX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.24 | -0.05 | 0.23 | 0.11 |
| FCF Yield | -9.41% | -8.76% | -3.51% | -3.27% |
| EV / EBITDA | -6.94 | -7.75 | -7.58 | -8.89 |
| Quality | ||||
| ROIC | -81.85% | -116.66% | -44.06% | -34.89% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.78 | 0.80 | 0.37 | 0.31 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -15.46% | -210.20% | 11.62% | 53.96% |
| Safety | ||||
| Net Debt / EBITDA | 1.98 | 1.60 | 3.21 | 3.36 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |